Literature DB >> 7726648

An evaluation of chemotherapy in patients with cancer of the cervix and lymph node metastases.

H T Ng1, C C Yuan, Y Y Kan, E S Ho, M S Yen, K C Chao.   

Abstract

During the past twelve years, out of the 288 cervical cancer patients who had lymph node involvement, the recurrence rate in the lymph node, was 26.6% if one or two nodes were involved and 50.8% if three or more nodes were involved (P < 0.0001). The recurrence rate of patients who received eight intravenous treatments (at monthly intervals) of multi-agent chemotherapy was lower than those who did not receive treatment. Of patients with one or two positive lymph nodes, 114 received treatment while 50 did not; their respective recurrence rates were 19.3% and 42.0%, a statistically significant difference (P < 0.025). Of patients with three or more positive lymph nodes, 97 received treatment and 27 did not, their respective recurrence rates, were 46% and 66% (P = 0.30) and the difference is not statistically significant. It would seem that multi-agent chemotherapy may reduce the recurrence rate in patients with cancer of the cervix and positive lymph nodes.

Entities:  

Mesh:

Year:  1995        PMID: 7726648     DOI: 10.1007/bf00634340

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  9 in total

1.  Pelvic lymph node metastasis of uterine cervical cancer.

Authors:  H Noguchi; I Shiozawa; Y Sakai; T Yamazaki; T Fukuta
Journal:  Gynecol Oncol       Date:  1987-06       Impact factor: 5.482

2.  Prognostic significance of single versus multiple lymph node metastases in cervical carcinoma stage IB.

Authors:  D J Tinga; P R Timmer; J Bouma; J G Aalders
Journal:  Gynecol Oncol       Date:  1990-11       Impact factor: 5.482

3.  A scoring system for predicting recurrence of cervical cancer.

Authors:  H.T. Ng; S.K. Shyu; Y.K. Chen; C.C. Yuan; K.C. Chao; Y.Y. Kan
Journal:  Int J Gynecol Cancer       Date:  1992-03       Impact factor: 3.437

4.  V factor (tumor volume) and T factor (FIGO classification) in the assessment of cervix cancer prognosis: the risk of lymph node spread.

Authors:  D Dargent; J L Frobert; G Beau
Journal:  Gynecol Oncol       Date:  1985-09       Impact factor: 5.482

5.  The outcome of the patients with recurrent cervical carcinoma in terms of lymph node metastasis and treatment.

Authors:  H T Ng; Y Y Kan; K C Chao; C C Yuan; S K Shyu
Journal:  Gynecol Oncol       Date:  1987-03       Impact factor: 5.482

6.  A pilot study of adjuvant therapy in patients with cervical cancer at high risk of recurrence after radical hysterectomy and pelvic lymphadenectomy.

Authors:  M S Wertheim; T B Hakes; A N Daghestani; D Nori; D H Smith; J L Lewis
Journal:  J Clin Oncol       Date:  1985-07       Impact factor: 44.544

7.  Prognostic factors in early invasive carcinoma of the uterine cervix. A clinical, histopathologic, and statistical analysis of 343 cases.

Authors:  G Larsson; P Alm; B Gullberg; H Grundsell
Journal:  Am J Obstet Gynecol       Date:  1983-05-15       Impact factor: 8.661

8.  Cervical carcinoma: a drug-responsive tumor--experience with combined cisplatin, vinblastine, and bleomycin therapy.

Authors:  M Friedlander; S B Kaye; A Sullivan; K Atkinson; P Elliott; M Coppleson; R Houghton; J Solomon; D Green; P Russell
Journal:  Gynecol Oncol       Date:  1983-10       Impact factor: 5.482

9.  Prognostic factors and operative treatment of stages IB to IIB cervical cancer.

Authors:  E Burghardt; H Pickel; J Haas; M Lahousen
Journal:  Am J Obstet Gynecol       Date:  1987-04       Impact factor: 8.661

  9 in total
  2 in total

Review 1.  Adjuvant platinum-based chemotherapy for early stage cervical cancer.

Authors:  Daniela D Rosa; Lídia R F Medeiros; Maria I Edelweiss; Paula R Pohlmann; Airton T Stein
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

Review 2.  Adjuvant platinum-based chemotherapy for early stage cervical cancer.

Authors:  Frederico S Falcetta; Lídia Rf Medeiros; Maria I Edelweiss; Paula R Pohlmann; Airton T Stein; Daniela D Rosa
Journal:  Cochrane Database Syst Rev       Date:  2016-11-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.